Introduction: Myositis is a broad diagnosis with a number of potential causes. There are numerous drugs that can lead to myotoxicity. We discuss a case of a patient with known rheumatoid arthritis who developed myositis with no evidence of an additional autoimmune condition and where the most likely cause seems to be leflunomide. Case description: A 46-year-old Asian lady with a background of seropositive rheumatoid arthritis and overactive bladder developed increasing muscle weakness. Disease activity was well-controlled on leflunomide which had been started four years ago after an initial trial of methotrexate proved ineffective. Other regular medications include tolterodine and rigevidon (combined oral contraceptive pill), paracetamol and co-codamol. She presented to her GP in February with generalised muscle weakness, fatigue, dry mouth, hair loss and occasional shortness of breath on exertion. Blood tests showed elevated CK at 1132 u/l, ALT 57 u/l (AST normal),LDH 302 u/L, CRP 4 mg/l and ESR 25mm/h. Further tests were subsequently arranged following rheumatology review including ANA and ENA (both negative), an extended myositis panel and HMGCoAR antibodies (also negative). MRI of her lower limbs showed bilateral oedema within the anterior and lateral muscle compartments of her thighs, worse on the left, and in keeping with myositis. Given the possibility of leflunomide being the cause of her symptoms it was stopped. Her CK one month after stopping leflunomide had decreased to 819 u/l and then 389 u/l after four months. The patient reported improvement in her muscle weakness, CK is currently being monitored, and she is awaiting an EMG. A muscle biopsy has been discussed with her previously and although she had refused initially, in view of persistent mild elevation in CK, the biopsy and leflunomide washout will be discussed again with her again. As she is clinically asymptomatic and not keen to try new medications, further immunosuppression has not been started. Discussion: Myositis is seen in a wide range of conditions with numerous possible causes. It can be drug-induced, secondary to viral infections or caused by autoimmune conditions including overlap conditions and idiopathic inflammatory myopathies. Drug-induced myositis is most commonly associated with statins, but has been seen with many different medications. Leflunomide is a disease-modifying anti rheumatic drug used particularly in the treatment of inflammatory arthritis but has also been used in treatment resistant dermatomyositis. It inhibits the mitochondrial enzyme, dihydroorotate dehydrogenase to reduce the reproduction of rapidly dividing cells. A rise in CK is considered a common side effect. We have only found one other case report where leflunomide was suspected to have induced polymyositis, also in a patient with rheumatoid arthritis. Both biochemical and clinical improvement following cessation of leflunomide, with no other inventions raises the likelihood of this being a leflunomide-induced myositis. Key learning points: When faced with a patient with rheumatoid arthritis presenting with symptoms suggestive of myositis, whilst anoverlap autoimmune condition is a possibility, it is important to consider potential drug causes. Numerous drugs have been implicated through both direct myotoxicity and immunologically mediated myotoxicity. Importantly for rheumatologists these can include glucocorticoids, antimalarial drugs, colchicine and tumour necrosis factor inhibitors. According to the summary of product characteristics a rise in CK is commonly seen with leflunomide butclinicalmyositishas only been reportedrarely. Conflicts of interest: The authors have declared no conflicts of interest. Introduction: Connective tissue diseases can present a diagnostic odyssey both for the patient and the practitioner. Here, the clinicaljourney of a patient with hypomyopathic dermatomyositis and mannose-binding lectin deficiency is described, demonstrating the interaction between complex co-morbidities and highlighting the importance of recognising different phenotypes of dermatomyositis. The case addresses the therapeutic challenges of conflicting immunological requirements, the importance of monitoring for infective complications, and is also a rare example of long-term IVimmunoglobulin therapy. Case description: A 47-year-old female with no significant medical history presented with an insect bite on her breast which subsequently began to discharge and ulcerate, unresponsive to oral antibiotics. Shortly after, shedeveloped painful swelling of fingers, knees, ankles and shoulders, followed by widespread itching and a blistering rash on her arms, upper torso and face. Examination was remarkable for peri-orbital oedema, retinal cotton wool spots and alopecia. Her investigations at this time revealed positive ANA, anti-Ro and raised CK. Skin biopsy was suggestive of dermatomyositis, but MRI of thighs, EMG and nerve conduction studies were normal. Other results included raised ESR, low lymphocytes and normal CRP. An initial diagnosis of SLE/dermatomyositis overlap was made; she was treated with IV methylprednisolone and discharged on hydroxychloroquine and prednisolone. Following this, she developed new areas of extensive and dramatic vasculitic skin ulceration on her face, fingers and elbows. Immunosuppressive therapy was escalated with increased dose of hydroxychloroquine and commencement of azathioprine. However, she then developed recurrent infections at the site of the ulcers as well as two episodes of infective tenosynovitis. Despite reduction of immunosuppression, she required multiple admissions to hospitals for intravenous antibiotics. Eventually, investigation into her recurrent infections revealed a complete, homozygous mannose-binding lectin (MBL) deficiency. In light of her severe symptoms and obvious risk for ongoing immunosuppression, it was decided that she would be a candidate for IV immunoglobulin (IVIG) therapy. Monitoring the evolution of the clinical picture over time led to a diagnosis of hypomyopathic dermatomyositis, positive for MDA-5 autoantibody. She has responded well to the IVIG with improvement of skin manifestations and no further infections. She has developed pulmonary fibrosis, but this has been extremely well controlled. However, her disease has been further complicated by the development of a peripheralneuropathy, which is still currently under investigation. Discussion: This is a fascinating case of a rare subset of dermatomyositis, thetreatment ofwhichwascomplicatedbyconcurrentMBLdeficiency.Itis interestingtonotethatMBLdeficiencyisactuallyimplicatedinthedevelopment of autoimmune conditions, in particular dermatomyositis. Other immunodeficiency conditions linked to dermatomyositis include X-linked agammaglobulinaemiaandhemophagocyticlymphohistiocytosis. As specialists who regularly use immunosuppressive agents, it is important for rheumatologists to be vigilant about the potential for infective complications, and to consider investigating for another underlying diagnosis if infections become more recurrent or severe than expected. Indeed, in the case of MBL deficiency, there would likely never be any clinical manifestation without precipitation by additional immunosuppressive therapy. This diagnosis prompted the decision to use regular IVIG therapywhich hasbeen successfulin controlling the disease. It is interesting to note that the patient is anti-MDA-5 antibody positive, which characteristically produces an amyopathic phenotype with rapidly progressive interstitial lung disease. In fact, her lung disease has been extremely stable and mostly asymptomatic. Whether this is due to the IVIG isunclear.A2018casereportdescribedanMDA-5positivedermatomyositis/scleroderma overlap without ILD and with sensory neuropathy. This also raises the question of whether her neurological manifestations could be linked to dermatomyositis. Initially, she presented with bilateral sensory neuropathy in both feet, and it was thought to be a potential feature of her condition. However, she subsequently developed sudden loss of power in her leg, and further investigations have concluded that she most likely has multiplesclerosis(MS).ThisiscertainlyplausibleduetoherunderlyingMBL deficiency which predisposes her to development of autoimmune conditions, but it would be interesting to discuss whether this could potentially stillbeapartofthedermatomyositis.
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